A Study of Belzutifan (MK-6482) in Participants With Renal Impairment (MK-6482-021)

Inclusion criteria

For Participants With Healthy Renal Function

• Is in good health based on the opinion of the investigator.
• Male participants agree to remain abstinent from heterosexual intercourse on a long-term basis or must agree to use contraception as instructed.
• Female participants must be of nonchildbearing potential.

For Participants With end stage renal disease (ESRD)

• With exception of the renal impairment, is in good health based on the opinion of the investigator.
• Has ESRD maintained on stable regimen of at least 3 times per week hemodialysis (HD) for at least 3 months prior to the initial administration of the study intervention.
• Male participants agree to remain abstinent from heterosexual intercourse on a long-term basis or must agree to use contraception as instructed.
• Female participants must be of nonchildbearing potential.

Exclusion criteria

For Participants With Healthy Renal Function

• Has a history of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases.
• Has a history of cancer (malignancy).
• Is positive for hepatitis B surface antigen (HBsAg), hepatitis C antibodies or human immunodeficiency virus (HIV).
• Had major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the prestudy (screening) visit.
• Has received any non-live vaccine starting from 14 days prior to study intervention or is scheduled to receive any non-live vaccine through 30 days following study intervention (except coronavirus disease 2019 [COVID-19]).

Participants With ESRD

• Has a history of cancer (malignancy).
• Has required frequent emergent HD (≥3) within a year prior to the initial dose of study intervention.
• Is positive for HBsAg, hepatitis C antibodies, or HIV.
• Had major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the prestudy (screening) visit.
• Has received any non-live vaccine starting from 14 days prior to study intervention or is scheduled to receive any non-live vaccine through 30 days following study intervention (except COVID-19)